REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Up 18.4% in December

REGENXBIO Inc. (NASDAQ:RGNX) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 6,230,000 shares, a growth of 18.4% from the November 30th total of 5,260,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is presently 6.1 days.

Analyst Ratings Changes

RGNX has been the topic of several recent research reports. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Chardan Capital restated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Raymond James restated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th. Morgan Stanley reissued an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research note on Friday, November 15th. Finally, HC Wainwright lowered their price objective on REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $35.27.

REGENXBIO Stock Down 5.8 %

NASDAQ:RGNX opened at $7.41 on Monday. The stock’s fifty day moving average is $9.27 and its two-hundred day moving average is $10.94. REGENXBIO has a 52 week low of $7.15 and a 52 week high of $28.80. The stock has a market capitalization of $367.13 million, a price-to-earnings ratio of -1.47 and a beta of 1.24.

Insider Transactions at REGENXBIO

In other news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the transaction, the director now directly owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 46.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.13% of the stock is currently owned by corporate insiders.

Institutional Trading of REGENXBIO

A number of institutional investors have recently bought and sold shares of RGNX. FMR LLC increased its holdings in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares in the last quarter. nVerses Capital LLC lifted its position in REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. increased its position in REGENXBIO by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 3,720 shares during the last quarter. Arizona State Retirement System boosted its holdings in REGENXBIO by 20.6% in the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 1,997 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in REGENXBIO during the 3rd quarter worth approximately $140,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.